Viyash Scientific Ltd (VIYASH) is currently trading at 218.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Viyash Scientific Limited (formerly Sequent Scientific) is a vertically integrated pharmaceutical and animal health company operating across APIs, human and animal formulations, and CDMO services with global markets including the US, Europe, India and emerging markets such as Turkey, Brazil and Mexico. Q1 FY27 results posted revenue of Rs. 946 crores, 19.5% year‑on‑year growth, adjusted EBITDA of Rs. 205 crores expanding margins to 21.6%, and PAT of Rs. 79 crores with net debt reduced to Rs. 86 crores, delivering a near‑net‑debt‑free balance sheet and substantial improvement in EBITDA‑to‑PAT conversion. Management states integration is complete and the company is prioritizing companion animal growth via the BioForLife Italy acquisition, expanding domestic fieldforce, and adding tablet manufacturing and R&D capabilities to support product launches and geographic extensions over the next 24 months. Strategic emphasis on backward integration and complex formulations is visible in the US and human formulation business, where shifting API manufacture to India and securing CDMO partnerships has driven higher margins, improved market share and a pathway to first‑to‑file, high‑potent oncology opportunities with commercialization expected from 2029 onward.

Over the past 52 weeks, Viyash Scientific Ltd has traded between a low of ₹178.40 and a high of ₹297.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Viyash Scientific Ltd has a market capitalization of approximately 9,933.05. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Viyash Scientific Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 46.46 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 9,933.05 Cr, Viyash Scientific Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Viyash Scientific Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Viyash Scientific Ltd is 46.46. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

CA Harbor Investments and CA Hull Investments sold a combined 5,03,65,847 equity shares in open market transactions on August 26, 2026.

Viyash Scientific reported consolidated PAT of ₹793 million for Q1 FY27, up 114.9% year-on-year from ₹369 million.

Consolidated revenues were ₹9,464 million (up 19.5% YoY), EBITDA (excluding ESOP costs) was ₹2,047 million (up 59.2% YoY), and PAT was ₹793 million (up 114.9% YoY).

Viyash Scientific, through its wholly owned subsidiary Alivira Animal Health, is acquiring 100% of BioForLife Italia S.r.l., a pet care company based in Milan.